MARKSANS329.00

Marksans Pharma Ltd.

· Pharma & Health
₹ CrorePeersGRANULESMETROPOLISPARKHOSPSJLHLHCGRUBICONSHILPAMEDSPARCMcap ₹14,909 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+1025.1+16.4
EBITDA+1036.5+14.5
Net Income+997.9+15.5
EPS (adj.)+10.5
Total Assets+1091.8+20.0
Total Equity+1126.3+21.0
Free Cash Flow+9608.0+289.7
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.